PCM
RARE icon

Prelude Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Prelude Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,681
Closed -$461K – 1332
2025
Q2 		$461K Buy
+12,681
New +$457K 0.04% 465
2025
Q1 		– Sell
-5,822
Closed -$245K – 1466
2024
Q4 		$245K Sell
5,822
-4,838
-45% -$240K 0.02% 894
2024
Q3 		$592K Buy
10,660
+4,460
+72% +$227K 0.04% 561
2024
Q2 		$255K Sell
6,200
-15,188
-71% -$648K 0.02% 865
2024
Q1 		$999K Buy
21,388
+16,488
+336% +$778K 0.05% 402
2023
Q4 		$234K Buy
+4,900
New +$190K 0.02% 864
2023
Q3 		– Sell
-4,788
Closed -$221K – 1314
2023
Q2 		$221K Buy
+4,788
New +$222K 0.01% 802
2022
Q4 		– Sell
-6,119
Closed -$253K – 1562
2022
Q3 		$253K Buy
+6,119
New +$314K 0.01% 954
2022
Q1 		– Sell
-2,759
Closed -$232K – 2151
2021
Q4 		$232K Buy
+2,759
New +$224K 0.01% 1481
2021
Q3 		– Sell
-3,869
Closed -$369K – 1980
2021
Q2 		$369K Buy
3,869
+1,884
+95% +$196K 0.01% 1109
2021
Q1 		$226K Buy
+1,985
New +$270K 0.01% 1275
2020
Q4 		– Sell
-794
Closed -$65K – 1854
2020
Q3 		$65K Sell
794
-4,728
-86% -$392K ﹤0.01% 1054
2020
Q2 		$432K Buy
+5,522
New +$365K 0.02% 503
2019
Q2 		– Sell
-129
Closed -$9K – 2061
2019
Q1 		$9K Buy
+129
New +$7.37K ﹤0.01% 1474
2016
Q2 		– Sell
-2,993
Closed -$189K – 1706
2016
Q1 		$189K Buy
+2,993
New +$196K 0.03% 579

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Prelude Capital Management's RARE Position: Q3 2025 in Review

Prelude Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 12,681 shares — an estimated $461K sold.

Prelude Capital Management first reported a position in RARE in Q1 2016 and held it in 15 quarters. The position peaked at $999K in Q1 2024. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Prelude Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 12,681 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $461K.
  • Prelude Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2016 and held it in 15 quarters.
  • Prelude Capital Management's Ultragenyx Pharmaceutical position peaked at $999K in Q1 2024.
  • 302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.